# Specification Quality Checklist: Hemostasis & Coagulation Decision Rules

**Purpose**: Validate specification completeness and quality before proceeding to planning
**Created**: 2026-09-29
**Feature**: [spec.md](../spec.md)

## Content Quality

- [x] No implementation details (languages, frameworks, APIs) — file names appear only in the "what the engine already does" evidence table
- [x] Focused on user value and business needs
- [x] Written for non-technical stakeholders (clinical reviewer)
- [x] All mandatory sections completed

## Requirement Completeness

- [x] No [NEEDS CLARIFICATION] markers remain — Q1–Q3 answered; D6 and D10 answered in the clarify session; D7–D9, D11, D12 deferred with default "engine unchanged"
- [x] Requirements are testable and unambiguous
- [x] Success criteria are measurable
- [x] Success criteria are technology-agnostic
- [x] All acceptance scenarios are defined
- [x] Edge cases are identified
- [x] Scope is clearly bounded (buckets A/B/C, diagnosis-labeling boundary)
- [x] Dependencies and assumptions identified

## Feature Readiness

- [x] All functional requirements have clear acceptance criteria
- [x] User scenarios cover primary flows
- [x] Feature meets measurable outcomes defined in Success Criteria
- [x] No implementation details leak into specification

## Notes

- Clarify session 2026-09-29: 5 of 5 questions used (DIC = C, ranges kept = A, scope = A, PLT ≥ 1000 tier = B, hemophilia bands = A).
- D7, D8, D9, D11, D12 remain open for a later `/speckit-clarify`; each defaults to "not applied".
- Input inconsistencies flagged for the reviewer: hemophilia mild "6–30 % (or > 5 %)" (D10); ADAMTS13 "≤ 5–10 % (or < 10–20 %)" with an unspecified 10/20–30 % gap (D8); "Extreme thrombocytosis" and "ITP" thresholds have no engine counterpart (D6).
- Next free register number: `P61`.
